Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome
Braz. J. Pharm. Sci. (Online)
;
58: e19868, 2022. tab
Article
in English
| LILACS
| ID: biblio-1383982
ABSTRACT
Abstract The aim of our study was to assess risk factors for potential drug-drug interactions (pDDIs) of statins across different phases of treatment of acute coronary syndrome (ACS) patients from the point of first medical contact to the coronary angiography (first phase), after coronary angiography to the last day of hospitalization (second phase) and at discharge from hospital (third phase). This was a post hoc analysis of the data collected during the retrospective observational cohort study conducted at the Clinic for Cardiology of the Clinical Centre Kragujevac, Serbia. Patients prescribed statins were identified from the original study population 156, 240 and 236 patients for the first, second and third phases, respectively. At least one statin pDDI was present in 113 (72.4%), 161 (67.1%) and 139 (58.9%) patients in the first, second and third phases, respectively. Heart failure, arrhythmias after ACS, CRP, triglycerides, length of hospitalization, number of prescribed drugs, antiarrhythmic drugs, and clopidogrel seem to increase the risk of statin pDDIs in at least one treatment phase. Physicians should be vigilant to the possibility of statin pDDIs in ACS patients who have factors that may increase their rate.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Patients
/
Risk Factors
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Drug Interactions
/
Acute Coronary Syndrome
Type of study:
Etiology study
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
English
Journal:
Braz. J. Pharm. Sci. (Online)
Journal subject:
Farmacologia
/
Teraputica
/
Toxicologia
Year:
2022
Type:
Article
Affiliation country:
Pakistan
Institution/Affiliation country:
University of Kragujevac/RS
Similar
MEDLINE
...
LILACS
LIS